AIP
ESPR

Arrowpoint Investment Partners’s Esperion Therapeutics ESPR Stock Holding History

Arrowpoint Investment Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,487
Closed -$107K – 115
2025
Q3 		$107K Buy
+40,487
New +$78.3K 0.11% 70

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowpoint Investment Partners's ESPR Position: Q4 2025 in Review

Arrowpoint Investment Partners sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 40,487 shares — an estimated $107K sold.

Arrowpoint Investment Partners first reported a position in ESPR in Q3 2025 and held it in 1 quarter. The position peaked at $107K in Q3 2025. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Arrowpoint Investment Partners reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 40,487 Esperion Therapeutics shares in Q4 2025, an estimated $107K.
  • Arrowpoint Investment Partners first reported a position in Esperion Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Esperion Therapeutics position peaked at $107K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Arrowpoint Investment Partners's 13F filing for Q4 2025, filed 11 Feb 2026.